Pricing Provides VENDAJETM Reimbursement in All MAC RegionsPOMPANO BEACH, FLORIDA., Jan. 24, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTCQB: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, announced that the Center for Medicare Services (“CMS”) has established national pricing of VENDAJETM in all Medicare Administrative Contractors (MAC) regions, effective January 1, 2023.
POMPANO BEACH, FLORIDA., August 16,2022 – BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, today announced it will host a conference call to discuss financial results for the quarter ended June30, 2022 and provide a corporate update on Monday, August22, 2022, at 4:30 pm EDT.
